Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Bioniche Life Sciences meets obligations under licensing agreement with Endo Pharmaceuticals

Bioniche Life Sciences Inc., a research-based, technology driven Canadian biopharmaceutical company, today announced that it has met the obligations associated with two milestones under its licensing agreement with Endo Pharmaceuticals for exclusive rights to develop and market Bioniche's proprietary product for non-muscle-invasive bladder cancer in North America.

15 Feb 2010

Genencor launches Accellerase DUET at the 15th Annual National Ethanol Conference in Orlando

Genencor, a division of Danisco A/S, today introduced Accellerase® DUET at the Renewable Fuels Association's 15th Annual National Ethanol Conference in Orlando, Fla. This product is the latest generation in the company's line of enzymes used to convert biomass into sugars, a critical step in the production of cellulosic ethanol and other advanced biofuels and biochemicals from non-food feedstocks.

15 Feb 2010

Positive interim results from Helix BioPharma's Topical Interferon Alpha-2b Phase II pharmacokinetic study

Helix BioPharma Corp. today announced that the first ten patients that have been enrolled in its Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions have completed the pharmacokinetic primary endpoint analyses with positive findings.

14 Feb 2010

First-quarter fiscal 2010 results announced by Agilent Technologies

Agilent Technologies Inc. today reported revenues of $1.21 billion for the first fiscal quarter ended Jan. 31, 2010, 4 percent above one year ago. First quarter GAAP net income was $79 million, or $0.22 per diluted share. Last year’s first quarter GAAP net income was $64 million, or $0.18 per share.

12 Feb 2010

New project to unravel secret lives of cancer cells may help produce new cancer therapies

A team of scientists from Princeton University and The Cancer Institute of New Jersey has embarked on a major new project to unravel the secret lives of cancer cells that go dormant and self-cannibalize to survive periods of stress. The work may help produce new cancer therapies to stem changes that render cancer cells dangerous and resistant to treatment.

12 Feb 2010

European Patent Office affirms validity of EuroMed's patent for Wrinkle-Resistant Wound dressings

EuroMed Inc. and Jentec Inc. today announced an important victory affirming the validity of a key patent, European patent number 1020198 (U.S. corresponding patent number 6878385) for Wrinkle-Resistant Wound dressings. In a ruling issued by the European Patent Office in Berlin, Germany, both of the grounds for opposition raised by the plaintiff, a prominent wound care manufacturer (i.e., extension of subject-matter, lack of ‘inventive step’ or sufficient originality) were not adequate cause to challenge the patent.

12 Feb 2010

Better and standardized animal models needed for musculoskeletal regenerative medicine

Clinical testing and development of novel therapies based on advances in tissue engineering and regenerative medicine that will one day enable the repair and replacement of diseased or damaged human muscle, bone, tendons, and ligaments depends on the availability of good animal models.

12 Feb 2010

NeoStem prices public offering of 5M common stock shares at $1.35 per share

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it priced a public offering of 5,000,000 shares of its common stock at $1.35 per share. Net proceeds from the offering, after underwriting discounts and commissions and expenses, will be approximately $5,697,500. NeoStem has granted the underwriters an option to purchase up to an additional 750,000 shares to cover over-allotments, if any.

12 Feb 2010

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

Mesa Laboratories reports fiscal third quarter results

Mesa Laboratories, Inc. today reported sales and earnings for both its fiscal third quarter and nine months ended December 31, 2009.

12 Feb 2010

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.

12 Feb 2010

iTech Medical signs manufacturing agreement with Thought Technology for MPR technology

iTech Medical, an information technology company, announced today that it has signed an exclusive, three-year manufacturing agreement with Thought Technology Ltd. of Montreal, Quebec for the Company’s proprietary Muscle Pattern Recognition (MPR) technology.

12 Feb 2010

Corgenix Medical files second-quarter Form 10-Q and reports financial results ended December 31, 2009

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, today filed its 2nd quarter Form 10-Q and reported its financial results.

11 Feb 2010

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

3SBio Inc., a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a Phase I clinical trial for NuPIAO to the Chinese State Food and Drug Administration (SFDA).

11 Feb 2010

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

QIAGEN N.V. and Celera Corporation today announced an agreement under which QIAGEN will distribute a Celera molecular multiplex assay. The assay is the next generation version of QIAGEN’s ResPlex II assay for detection of respiratory pathogens.

From QIAGEN Manchester Limited 11 Feb 2010

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2009. Consolidated results include the results of NeedleTech Products, Inc. (“NeedleTech”) subsequent to its acquisition by Theragenics on July 28, 2008.

11 Feb 2010

Boston Scientific combines Cardiovascular Group and Cardiac Rhythm Management Group

Boston Scientific Corporation today announced a series of management changes and restructuring initiatives designed to strengthen the Company and position it for long-term success.

11 Feb 2010

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.

11 Feb 2010

Simcere Pharmaceutical Group subsidiary receives Chinese SFDA approval for Zanamivir

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that one of its subsidiaries, Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd., has received new drug registration approval from the State Food and Drug Administration ("SFDA") to manufacture and sell Zanamivir, a neuraminidase inhibitor inhalant used in the prevention and treatment of Influenza A and Influenza B. Zanamivir is marketed globally by GlaxoSmithKline under the trade name Relenza.

11 Feb 2010

Boston Scientific rebuts HeartRhythm's cardiac resynchronization therapy defibrillator implantation article

Boston Scientific Corporation today rebutted an article published in the journal HeartRhythm. The article reported a case summary of a patient who had been implanted subcutaneously with a Cognis cardiac resynchronization therapy defibrillator. The article suggested a weakened header bond was responsible for the abnormal sensing and pacing impedance experienced by the patient.

11 Feb 2010

Manufacturing News and Research

Further Reading

Bioniche Life Sciences meets obligations under licensing agreement with Endo Pharmaceuticals

Genencor launches Accellerase DUET at the 15th Annual National Ethanol Conference in Orlando

Positive interim results from Helix BioPharma's Topical Interferon Alpha-2b Phase II pharmacokinetic study

First-quarter fiscal 2010 results announced by Agilent Technologies

New project to unravel secret lives of cancer cells may help produce new cancer therapies

European Patent Office affirms validity of EuroMed's patent for Wrinkle-Resistant Wound dressings

Better and standardized animal models needed for musculoskeletal regenerative medicine

NeoStem prices public offering of 5M common stock shares at $1.35 per share

Second-quarter fiscal 2010 results announced by Pharmacyclics

Mesa Laboratories reports fiscal third quarter results

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

iTech Medical signs manufacturing agreement with Thought Technology for MPR technology

Corgenix Medical files second-quarter Form 10-Q and reports financial results ended December 31, 2009

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

Boston Scientific combines Cardiovascular Group and Cardiac Rhythm Management Group

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Simcere Pharmaceutical Group subsidiary receives Chinese SFDA approval for Zanamivir

Boston Scientific rebuts HeartRhythm's cardiac resynchronization therapy defibrillator implantation article

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®